Mera Pharmaceuticals, Inc.
Other OTCTotal Valuation
Mera Pharmaceuticals, Inc. carries a market capitalization of 55,730.00, placing it among publicly traded companies globally.
| Market Cap | 55,730.00 |
| Enterprise Value | N/A |
Share Statistics
Mera Pharmaceuticals, Inc. currently has 547.27M shares outstanding.
| Shares Outstanding | 547.27M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3.62, and the price-to-book ratio stands at -0.12.
| PE Ratio | N/A |
| PS Ratio | 3.62 |
| PB Ratio | -0.12 |
| P/TBV Ratio | -1.27 |
| P/FCF Ratio | -15.75 |
| P/OCF Ratio | -15.25 |
Financial Position
Mera Pharmaceuticals, Inc. maintains a current ratio of 0.06, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.06 |
| Quick Ratio | 0.01 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -33.17 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -260.60 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -14,187.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Mera Pharmaceuticals, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Mera Pharmaceuticals, Inc. generated 302,624.00 in revenue and converted that into -187,680.00 in net income, yielding earnings per share of 0.00. EBITDA reached -192,754.00, while operating income came in at -201,054.00.
| Revenue | 302,624.00 |
| Gross Profit | 286,364.00 |
| Operating Income | -201,054.00 |
| Pretax Income | -201,867.00 |
| Net Income | -187,680.00 |
| EBITDA | -192,754.00 |
| EBIT | -201,054.00 |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
Total book value stands at -8.83M, with working capital of -880,830.00 providing operational flexibility.
| Cash & Cash Equivalents | 4,315.00 |
| Total Debt | N/A |
| Net Debt | -4,315.00 |
| Equity (Book Value) | -8.83M |
| Book Value Per Share | -0.02 |
| Working Capital | -880,830.00 |
Cash Flow
Mera Pharmaceuticals, Inc. produced -71,837.00 in operating cash flow over the past twelve months. After subtracting -2,288.00 in capital expenditures, free cash flow totaled -74,125.00 - equivalent to 0.00 per share.
| Operating Cash Flow | -71,837.00 |
| Capital Expenditures | -2,288.00 |
| Free Cash Flow | -74,125.00 |
| FCF Per Share | 0.00 |
Margins
Mera Pharmaceuticals, Inc. operates with a gross margin of 94.63, reflecting its pricing power and cost economics. The operating margin of -66.44 and net profit margin of -62.02 provide insight into operational efficiency.
| Gross Margin | 94.63 |
| Operating Margin | -66.44 |
| Pretax Margin | -66.71 |
| Profit Margin | -62.02 |
| EBITDA Margin | -63.69 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -6.62 |
| FCF Yield | -6.35 |
Scores
Mera Pharmaceuticals, Inc. posts an Altman Z-Score of -195.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -195.37 |